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HIV-1 infected persons develop a robust CTL response to HIV antigens, yet HIV-1 is able to evade this host response and
successfully replicate. The mechanism(s) of evasion is not completely defined but has been suggested to include resistance
of infected cells to CTL-mediated apoptosis. The HIV-1 Vpr protein induces G2 arrest by indirectly inhibiting activation of
cyclin B/p34cdc2 kinase. Granzyme B, the principle mediator of CTL-induced apoptosis, prematurely activates this same
kinase complex. Therefore, we assessed the susceptibility of HIV-1 infected cells to CTL-mediated apoptosis to determine
whether the expression of Vpr protected the infected cells from CTL-induced apoptosis. Antigen-specific CD8 CTL were
able to induce apoptosis in HIV-1 infected cells and cells labeled with peptide corresponding to the CTL epitope with
equivalent efficiency. This demonstrates that neither HIV-1 Vpr nor any other HIV protein directly inhibits CTL effector
functions. Furthermore, we confirm that HIV-1 Nef is able to provide partial protection from CTL recognition of infected cells.
Thus, the inability of CTL to control HIV-1 infection is likely not due to direct inhibition of CTL-mediated apoptosis. © 2002INTRODUCTION
MHC Class I-restricted CD8 CTL responses are es-
sential for controlling persistent viral infections in pri-
mates and mice (Heslop et al., 1994; Jamieson and
Ahmed, 1989; Posavad et al., 1997; Riddell and Green-
berg, 1995; Schmitz et al., 1999). Primary HIV or SIV
infection induces strong virus-specific CD8 CTL re-
sponses directed to several viral proteins that contribute
to the resolution of viremia (Borrow et al., 1994; Koup et
al., 1994; Musey et al., 1997; Schmitz et al., 1999) and the
maintenance of clinical latency (Harrer et al., 1996; Klein
et al., 1995; Ogg et al., 1998; Schmitz et al., 1999). How-
ever, the HIV-specific CTL responses elicited are unable
to completely curtail virus replication and are lost or
become dysfunctional with progression to AIDS (Car-
michael et al., 1993; Klein et al., 1995; Spiegel et al.,
2000). The failure to control HIV infection, despite the
strength and breadth of the CTL response, may reflect
the loss of antigen-specific CD4 T cell help needed to
support CD8 CTL (Rosenberg et al., 1997), evasion of
CTL by mutation of CTL epitopes (Borrow et al., 1997;
1 To whom correspondence and reprint requests should be ad-
dressed at Department of Pediatrics and Department of Molecular
Microbiology and Immunology, Oregon Health and Sciences University,13Goulder et al., 1997; Phillips et al., 1991), or HIV Nef-
mediated down-regulation of cell surface expression
of MHC Class I (Collins et al., 1998; Schwartz et al.,
1996).
Another potential mechanism by which HIV might
evade the CTL response is the inhibition by viral proteins
of CTL effector mechanisms. Upon recognition of the
target cell by CTL, the contents of cytotoxic granules,
perforin and granzymes, are released and induce target
cell death. Perforin forms pores in the plasma membrane
of the target cell that results in osmotic damage and
facilitates entry of granzymes into the target cell (Liu et
al., 1995). Granzyme B, one of the constituents of CTL
granules, induces apoptosis by directly activating some
pro-caspases (Thornberry et al., 1997) and by causing
the premature activation of cdc2 and cdk2 containing
kinase complexes (Chen et al., 1995; Shi et al., 1994,
1996a), which are important regulatory components of
the cell cycle. CTL-induced apoptosis has been reported
to be cell cycle dependent, perhaps reflecting the impor-
tance of granzyme B activation of cdc2 and cdk2 kinases
(Nishioka and Welsh, 1994).
HIV-1 Vpr arrests infected cells in the G2 phase of the
cell cycle by indirectly inhibiting the activation of the
cyclin B/p34cdc2 complex (Bartz et al., 1996; He et al.,
1995; Jowett et al., 1995; Re et al., 1995). While
the mechanism of Vpr-mediated inhibition of cyclinElsevier Science (USA)
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opposes the action of the same molecular complex as
granzyme B. Thus we hypothesized that HIV-1 vpr ex-
pression could potentially protect infected cells from
CTL-mediated killing (Emerman, 1996; He et al., 1995).
HIV-1 infected cells have been shown to be suscepti-
ble to CTL damage using a standard 51Cr release assay
(CRA) (Yang et al., 1996). However, this assay reflects
plasma membrane (perforin-mediated) damage and
does not directly measure apoptotic death. Thus, to di-
rectly assess the ability of HIV-1 gene products, partic-
ularly Vpr, to protect HIV-1 infected cells from CTL-medi-
ated apoptosis, we used assays that measure both mem-
brane damage and apoptosis. We observed that HIV-1
proteins, including Vpr, did not protect infected cells from
CTL-induced apoptosis. This indicates that HIV-1 is not
able to directly inhibit CTL effector mechanisms. How-
ever, we confirm that the HIV-1 Nef protein (Collins et al.,
1998) is able to delay killing of HIV-1 infected cells
through down-regulation of MHC Class I molecules.
RESULTS
Preparation of target cells for CTL assays
We wanted to determine whether HIV-1 Vpr or other
HIV-1 proteins protect infected cells from CTL-mediated
apoptosis. Jurkat T cells were selected as target cells
because they expressed the HLA-A3 molecule required
to present the HIV-1 Gag (MA) epitope to CTL clone
28A2-15. We used VSV G pseudotyped HIV-1 that was
deleted of env to establish greater than 95% infection of
the Jurkat cells (Fig. 1A). As expected, Jurkat cells in-
fected with the Vpr virus accumulated in the G2 phase
of the cell cycle, whereas cells infected with the Vpr
virus exhibited no cell cycle perturbations compared to
uninfected cells (Fig. 1B). Because we could productively
infect nearly 100% of the Jurkat cells, we were able to
directly compare the ability of CTL to induce apoptosis in
HIV-1 infected cells expressing all HIV-1 proteins (except
Env), HIV-1 infected cells expressing all HIV-1 proteins
FIG. 1. Infection and G2 arrest of VSV G pseudotyped HIV-1env infected Jurkat T cells. (A) Jurkat cells infected with VSV G pseudotyped HIV-1 are
nearly 100% infected. Jurkat cells were analyzed for percentage infection using a mAb to p24 and detection by flow cytometry. P24 antigen expression
as measured by fluorescence intensity is on the x-axis and relative cell number is on the y-axis. The left, middle, and right panels are uninfected, HIV-1
Vpr infected, and HIV-1 Vpr infected cells, respectively. (B) Vpr mediates G2 arrest of infected T cells. Infected cells were analyzed for DNA content
by propidium iodide staining of DNA and flow cytometry at 36 h postinfection. The left, middle, and right panels are uninfected, HIV-1 Vpr infected,
and HIV-1 Vpr infected cells, respectively.
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except Vpr and Env, and control cells labeled with the
cognant epitope but expressing no HIV proteins.
Apoptosis of target cells by CD8 CTL was measured
using the TUNEL method with analysis by flow cytometry.
The CTL clones are smaller than the target Jurkat cells
and could easily be distinguished from Jurkat cells by
forward- and side-scatter properties (Fig. 2). Thus, by
gating only on the Jurkat cells we were able to selectively
analyze the target cells and exclude the CTL from the
analysis for the amount of apoptosis. A representative
analysis is shown in Fig. 2. After incubation with CTL,
apoptosis is induced in the peptide-labeled cells (43%)
but not in mock-treated cells (2%). The addition of anti-
bodies that block Fas/FasL (CD95/CD95L) interaction did
not affect target cell lysis mediated by the CTL clone,
indicating that rapid apoptosis is most likely occurring
via perforin/granzyme-mediated mechanisms (data not
shown).
Comparison of CTL-mediated membrane lysis versus
CTL-mediated apoptosis
To test the hypothesis that vpr HIV-1 would inhibit
granzyme but not perforin function, we used the chro-
mium release assay and TUNEL assay to distinguish
between perforin- and granzyme-mediated events, re-
spectively. If HIV-1 Vpr selectively interfered with CTL-
mediated apoptosis, a reduction in apoptosis (measured
by TUNEL assay) relative to membrane damage (mea-
sured by chromium release) at the same effector to
target cell ratio would be expected. Chromium release
from HLA-A3 Jurkat target cells incubated with the
CD8 CTL clone 28A2-15 was equivalent in cells infected
with vpr virus, cells infected with vpr virus, or cells
labeled with the peptide epitope (Fig. 3A). This demon-
strates that Jurkat cells infected with HIV and expressing
all viral proteins except Env are as sensitive as peptide-
loaded targets to perforin-mediated CTL damage.
Samples set up in parallel were analyzed for CTL-
mediated apoptosis. The TUNEL assay showed equiva-
lent apoptosis induced by CD8 CTL in HIV-infected
targets and peptide-loaded targets, indicating that ex-
pression of viral proteins, including Vpr, from the inte-
grated provirus could not inhibit apoptosis (Fig. 3B). It is
unlikely that an inhibitory effect on apoptosis was over-
come by excessive CTL, because no inhibitory effect
was seen even at the lower CTL to target cell ratios. Vpr
FIG. 2. Induction of apoptosis in peptide-labeled cells by CTL clone 28A2-15. CTL were added to mock-labeled cells (top) at an E:T ratio of 0.25:1
and to peptide-labeled cells (middle) at an E:T ratio of 0.05:1. The arrows point to the CTL population. The left panels are the forward- and side-scatter
distributions of the CTL and target cells. In the middle panels, apoptosis is measured by increased fluorescent intensity on the y-axis versus
forward-scatter on the x-axis. The right panels are histogram representations of the apoptosis detected in target cells falling within the gates drawn
in the left panels.
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has been reported to both induce and inhibit apoptosis
and it has been suggested that the opposing functions of
these proteins may operate at different times in the viral
life cycle (Ayyavoo et al., 1997). However, we assayed
CTL-induced apoptosis of infected target cells at both 24
and 48 h postinfection and found that the cells were
equally susceptible to apoptosis at either time-point
(data not shown). Thus, our data suggest that Vpr ex-
pressed from the provirus does not affect CTL-mediated
apoptosis during the viral life cycle.
The HIV-1 Nef protein has previously been reported to
protect HIV-1 infected cells from CTL killing by removing
HLA molecules from the surface of infected cells, result-
ing in decreased recognition of HIV-1 infected cells. We
also tested an HIV-1 virus in which both Vpr and Nef
were deleted. However, Jurkat cells infected with this
virus did not show increased susceptibility to CTL killing
compared to wild-type HIV-1 or HIV-1Vpr infected cells
(data not shown). This is consistent with the results
reported by others that down-regulation of HLA by Nef
has negligible results on target cell recognition in trans-
formed cell lines (Yang et al., 1996).
We also tested an additional CTL clone to rule out the
possibility that the inability of HIV-1 proteins to protect
against CTL-induced apoptosis was due to properties
unique to CTL clone 28A2-15. CTL clone 1-1b recognizes
an Mtb epitope, Mtb11/CFP10 (aa 2–11), in the context of
HLA B44. Jurkat cells engineered to constitutively ex-
press HLA class I B44 were infected with VSV G
pseudotyped HIV-1env either Vpr or Vpr. Prior to the
CTL assays the target cells were pulsed with the peptide
representing the cognate epitope of clone 1-1b. As ob-
served with CTL clone 28A2-15, HIV-1 proteins, including
Vpr, were not able to protect from CTL-induced apoptosis
(Table 1).
Analysis of CTL-induced apoptosis in primary CD4 T
cells infected with HIV-1 or HIV-1vpr
Jurkat T cells are a leukemic cell line and may have
evolved different sensitivities to apoptosis, relative to
nontransformed cells, during the process of transforma-
tion. Thus, we also assessed CTL-induced apoptosis in
HIV infected primary CD4 T cells. Because we are
unable to establish 100% infection we could not directly
compare the susceptibility of HIV-1 infected cells to CTL-
mediated apoptosis to the susceptibility of peptide-la-
beled targets to CTL-mediated apoptosis. However, we
were able to compare the susceptibility of cells infected
with isogenic strains of HIV-1 containing mutations of
various accessory genes (vpr or nef ). To analyze apopto-
sis in HIV-1 infected cells, we first labeled apoptotic cells
by TUNEL and then labeled infected cells using a mAb to
p24 (Fig. 4A). Mock- and peptide-labeled targets were
analyzed by staining the sample with anti-CD8 antibody
and gating out the CTL population. We found primary
CD4 T cells infected with HIV-1env or HIV-1envvpr
to be equally susceptible to apoptosis induced by the
HIV-specific CD8 CTL clone 28A2-15 (Fig. 4B). These
results demonstrate that Vpr does not protect primary
CD4 T cells infected with HIV-1 from CTL-mediated
apoptosis.
We also assessed the susceptibility of primary CD4 T
cells infected with HIV-1 containing a deletion of the nef
gene. Nef has been reported to protect HIV-1 infected
primary CD4 T cells from CTL recognition by removing
MHC/peptide complexes from the cell surface. We
wanted to confirm that Nef was protective in primary
cells as well as confirm that we would be able to detect
HIV-1 genes that provide some level of protection from
CTL using the TUNEL assay. Deletion of Nef increased
the susceptibility of HIV-1 infected CD4 cells to CTL-
mediated killing by approximately twofold in this assay
(Fig. 4B). Thus, we confirm that HIV-1 Nef can partially
protect infected primary cells from CTL-mediated killing
and demonstrate that HIV-1 Vpr cannot protect from CTL-
mediated apoptosis.
DISCUSSION
Infection with HIV induces a vigorous CD8 CTL re-
sponse. Nonetheless, these effectors fail to completely
curtail HIV-1 infection. Inhibition of CTL-mediated apop-
TABLE 1
51Cr Release and Apoptosis in Peptide-Labeled and HIV-1 Infected
Target Cells Incubated with CTL Clone
51Cr release Apoptosis
Mock (0) 0.5%
Peptide 25% 31%
HIV-1env 30% 24%
HIV-1envvpr 20% 23%
Note. Target cells were incubated with the CTL clone at an E:T ratio
of 1:1. The (0) designates that the percentage 51Cr release was below
the level of spontaneous 51Cr release.
FIG. 3. CTL effector function mediated by 28A2-15 as measured by a
51Cr release assay and by TUNEL. Target cells are Jurkat cells that were
mock-infected, incubated with peptide RLRPGGKKK, infected with vpr
virus, or infected with vpr virus and were used at 40 h postinfection. (A)
Chromium release assay results are the means of triplicates at each E:T
ratio. (B) TUNEL results are derived from 5000 to 10,000 gated events.
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tosis has been proposed as a mechanism by which
viruses can elude host defense (Teodoro and Branton,
1997). However, the direct demonstration that viral anti-
apoptotic proteins inhibit CD8 CTL-mediated apoptosis
is lacking (Trapani et al., 1999). Because HIV-1 Vpr inhib-
its both apoptosis (Ayyavoo et al., 1997; Conti et al., 1998;
Fukumori et al., 1998) and activation of p34cdc2 (Bartz et
al., 1996; He et al., 1995; Jowett et al., 1995; Re et al.,
1995), the kinase complex activated by the CTL effector
protein granzyme B, we hypothesized that the activity of
Vpr would render HIV infected cells refractory to CTL-
mediated apoptosis. HIV-1 proteins Vpr (Ayyavoo et al.,
1997; Conti et al., 1998; Fukumori et al., 1998) and Tat
(Gibellini et al., 1995; McCloskey et al., 1997; Zauli et al.,
1993, 1995) have been reported to inhibit apoptosis in
vitro. In addition, in vivo, HIV-1 infected cells are rarely
observed to undergo apoptosis (Finkel et al., 1995).
These observations support the hypothesis that HIV pro-
teins may protect infected cells from apoptosis. How-
ever, our study demonstrates that Vpr expressed by HIV
infected T cells cannot protect these cells from CTL-
mediated apoptosis. However, we confirm that HIV-1 Nef
down-regulation of MHC I cell surface expression is able
to protect HIV-1 infected CD4 T cells from CTL killing.
The failure to observe an effect of HIV-1 Vpr on CTL-
mediated apoptosis could be due to redundant mecha-
nisms employed by CTL to induce apoptosis (Trapani et
al., 1999). Although granzyme B may be the most impor-
tant effector molecule by which CTL induce apoptosis,
additional cytotoxic granule constituents, such as gran-
zyme A, can induce apoptosis as well. In addition, gran-
zyme B can activate multiple steps in apoptotic pathways
including direct cleavage of the DNA fragmentation fac-
tor 45 (Sharif-Askari et al., 2001), cleavage of caspases
(Darmon et al., 1996; Shi et al., 1996b; Van de Craen et al.,
1997), cleavage of nuclear lamins (Zhang et al., 2001),
and activation of the mitochondrial arm of apoptotic path-
ways (Pinkoski et al., 2001). Confirming our results, it has
recently been demonstrated that granzyme B does not
have to proceed through p34cdc2 to activate apoptosis
(Waring and Mullbacher, 2001).
It could be argued that our experimental system is not
sufficiently sensitive to detect the effect of Vpr on apop-
totic inhibition. Since it is known that the nef gene prod-
uct can prevent CTL killing of HIV-1 infected cells
through the down-regulation of MHC class I molecules
(Collins et al., 1998), we tested the effect of Nef. Here we
show that HIV-1 Nef can provide partial protection from
CTL killing in primary T cells. Furthermore, positive and
negative controls of our assay system in Jurkat cells
showed that we could detect CD95 (Fas)-mediated apop-
tosis of Jurkat cells and detect blocking of this apoptosis
using a CD95 blocking antibody (data not shown).
How does HIV continue to successfully replicate in the
face of a strong CTL response? Deficits in CTL homing to
virus-infected lymph nodes, recognition of infected target
cells, effector function, or survival, could all potentially
contribute to poor control of virus replication. Impaired
recognition of HIV-1 infected cells due to viral mutations
in regions containing CTL epitopes (Borrow et al., 1997;
Goulder et al., 1997; Phillips et al., 1991) and due to HIV
Nef-mediated down-regulation of MHC Class I (Collins et
al., 1998) has been documented. In addition, the loss of
viral control with progression to AIDS correlates with the
loss of functional CTL. While virus-specific CD8 T cells
can be detected in patients with severe CD4 depletion
FIG. 4. Equivalent induction of apoptosis in primary CD4 T cells
infected with HIV-1 Vpr or HIV-1 Vpr. (A) Primary flow cytometry data
of apoptosis detection by TUNEL in target cells. Target cells are
primary CD4 T cells that were mock infected, infected with a vpr
virus, infected with vpr virus, or infected with nef virus. Target cells
were used at 40 h postinfection. Mock- and peptide-labeled target
samples were stained with anti-CD8 to gate out the CTL clone. HIV-1
infected targets were stained with anti-p24 to quantify apoptosis in HIV
infected cells. The analysis shown is for one replicate at an E:T ratio of
0.5:1. (B) TUNEL results for apoptosis in HIV-1 infected primary CD4 T
cells incubated with CTL clone 28A2-15. Results are the averages of
duplicate samples.
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using MHC Class I tetramers, (Spiegel et al., 2000) these
cells exhibited impaired IFN- release ex vivo.
CTL grown in vitro are able to kill infected cells via
perforin-mediated lysis (Yang et al., 1996) and by apopto-
sis, as we have demonstrated in this study. Moreover, we
have shown previously that HIV-specific CTL expanded
in vitro and adoptively transferred back into the autolo-
gous host are functional as reflected by antiviral activity
(Brodie et al., 1999). However, the antiviral effect was
short-lived and correlated with a rapid decline in the
survival of the adoptively transferred CTL. These individ-
uals were deficient in endogenous HIV-specific CD4 T
cell responses, suggesting that in this case and late in
disease the lack of endogenous CD4 T cell help may be
an important contributing factor to the decline in function
of CTL responses. Thus, therapeutic strategies designed
to provide cognate CD4 T cell help for HIV-specific CTL,
rather than interventions aimed at improving effector
function per se, may effect improvements in overall CTL
function and survival and promote control of HIV-1 rep-
lication.
MATERIALS AND METHODS
Cell lines
The Jurkat cell line, an HLA A3 T-leukemic cell-line
(Hakem et al., 1989), was obtained from the ATCC. A
Jurkat cell line expressing HLA B44 was provided by Dr.
Steve Fling (Corixa Corp., Seattle, WA). Jurkat cell lines
were maintained in RPMI supplemented with 25 mM
HEPES, 4 mM L-glutamine, 50 g/ml streptomycin, 50
U/ml of penicillin, and 11% FCS. EBV-transformed B lym-
phoblastoid cell lines (LCL) were established as previ-
ously described (Riddell and Greenberg, 1990) and main-
tained in the same medium used for Jurkat cells.
CD4 T cells for establishment of primary T cell lines
were isolated from PBMC (1  107) by staining with a
mAb to CD4 (Leu3A) and sorting by flow cytometry. CD4
T cells (1  105) were then used to establish primary
CD4 cell lines. CD4 cells were cultured in T-25 flasks
with 25 106 irradiated (3000 rad) PBMC as feeders and
stimulated with anti-CD3 (OKT3) at 30 ng/ml in RPMI
supplemented with 50 g/ml streptomycin, 50 U/ml pen-
icillin, 5 M -mercaptoethanol, and 10% human serum.
IL-2 was added the next day to 20 units/ml and then
added every 2–3 days. The cells were reexpanded every
2 to 3 weeks by restimulation with anti-CD3 mAb, fol-
lowed by IL-2 every 2–3 days as described for the initial
expansion. The CD4 T cells were used for infection at
days 10–14 poststimulation with anti-CD3 mAb.
Plasmids
All proviral plasmids are derived from pHIV-1Lai (Peden
et al., 1991) and have been previously described. The
proviral plasmid pHIV-1env expresses all viral proteins
except the HIV-1 envelope, and pHIV-1envvpr or pHIV-
1envnef expresses all viral proteins except for enve-
lope and Vpr or envelope and nef. The vesicular stoma-
titis virus G protein (VSV G) expression vector (pL-VSV G)
expresses VSV G protein under the control of the HIV-1
LTR and has been previously described (Bartz et al.,
1996).
Virus stocks
Virus stocks were prepared as previously described
(Bartz et al., 1996; Bartz and Vodicka, 1997). Briefly, 293T
cells were cotransfected with a HIV-1 proviral plasmid
and a VSV G expression plasmid. The pseudotyped virus
was harvested, concentrated by ultracentrifugation, ali-
quoted, and stored at 70°C. The titers of the viral
stocks were determined by the MAGI assay (Kimpton
and Emerman, 1992).
Synthetic peptides
The peptide RLRPGGKKK, recognized by the HIV-1
Gag-specific CTL clone, was synthesized as a free acid
by the Fred Hutchinson Cancer Research Center Bio-
technology Center (Seattle, WA). The peptide, AEMKT-
DAATL, which is the epitope recognized by the Myco-
bacterium tuberculosis (Mtb)-specific clone 1-1B was
synthesized by Corixa Corp.
Effector CTL clones
The HIV Gag-specific CD8 CTL clone 28A2-15 was
isolated from an HIV infected individual as described
previously (Riddell et al., 1996). The Mtb-specific CTL
clone 1-1B was isolated from a healthy individual latently
infected with Mtb, as previously described (Lewinsohn et
al., 2001). The CTL clones (2  105) were expanded by
stimulation every 14 days with anti-CD3 mAb (Ortho-
clone, 30 ng/ml) in the presence of irradiated allogeneic
LCL (5  106), PBMC (25  106), and IL-2 (20 U/ml) in
RPMI medium supplemented with 25 mM HEPES, 4 mM
L-glutamine, 50 g/ml streptomycin, 50 U/ml penicillin, 5
M -mercaptoethanol, and 11% human serum. The
clones were used 11–14 days after stimulation in the
cytotoxicity and apoptosis assays.
Infection with pseudotyped viruses
Jurkat cells (3  106) or primary CD4 T cells were
infected with VSV G pseudotyped HIV-1 (env, envvpr,
or envnef) at an m.o.i. of 10:1 in 100 l of medium in
the presence of DEAE–dextran (Pharmacia, 20 g/ml) for
2 h. The cells were washed and cultured in medium for
24 to 36 h (5 105 cells/ml) prior to use in the cytotoxicity
and apoptosis assays.
51Cr-release assay
Target cell membrane damage was assessed using a
standard 4-h CRA. Jurkat targets were cultured in the
18 LEWINSOHN ET AL.
presence of Na51Cr (50 Ci/ml) for 14 h. Jurkat cells
displaying the HIV-1 Gag peptide epitope were prepared
by the addition of peptide (100 ng/ml) at the time of 51Cr
labeling or by infection with the pseudotyped virus. B44
Jurkat cells displaying the Mtb peptide epitope were
prepared by the addition of peptide (10 g/ml) at the time
of infection with pseudotyped virus. Target cells were
placed on a Ficoll–Hypaque density gradient and
washed prior to incubation with the effector CTL clone at
various effector:target (E:T) ratios for 4 h at 37°C. Per-
centage specific lysis was calculated as previously de-
scribed (Riddell and Greenberg, 1990).
Apoptosis assay
CTL-mediated apoptosis of target cells was detected
using the Boehringer Mannheim in situ cell death detec-
tion kit, which is based on the TUNEL method, with
analysis by flow cytometry. Jurkat target cells pulsed with
peptide and/or infected with the pseudotyped virus were
prepared in a identical fashion to that described for the
chromium release assay and in parallel with the CRA
incubated with the effector CTL clone at various E:T
ratios for 1.5 h at 37°C. The samples were then prepared
for labeling by fixation with 1% paraformaldehyde in PBS
at 4°C for 1 h or overnight, permeabilized with 0.5%
Tween 20 in PBS, and labeled with FITC–dUTP according
to the manufacturer’s instructions. After the labeling pro-
cedure, the cells were analyzed by flow cytometry. Per-
centage specific apoptosis was calculated as ([% exper-
imental apoptosis  % baseline apoptosis]/[100  %
baseline apoptosis])  100. Baseline apoptosis was de-
fined as the percentage apoptosis of the target cell in the
absence of effector CTL clone.
Flow cytometry
Jurkat cells or primary CD4 cells infected with the
pseudotyped virus were analyzed for the percentage of
cells infected using an anti-p24 antibody and flow cytom-
etry, as described previously (Bartz et al., 1996).
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